Peripheral DES Presents Copious Early-Stage Reg Requirements – CDRH Staff
This article was originally published in The Gray Sheet
Executive Summary
FDA is warning peripheral drug-eluting stent manufacturers not to underestimate the utility of collaborating with the agency early in the preclinical process